Todd A. Hardy

4.9k total citations · 1 hit paper
73 papers, 2.5k citations indexed

About

Todd A. Hardy is a scholar working on Pathology and Forensic Medicine, Neurology and Molecular Biology. According to data from OpenAlex, Todd A. Hardy has authored 73 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Pathology and Forensic Medicine, 27 papers in Neurology and 20 papers in Molecular Biology. Recurrent topics in Todd A. Hardy's work include Multiple Sclerosis Research Studies (31 papers), Peripheral Neuropathies and Disorders (20 papers) and Retinal and Optic Conditions (9 papers). Todd A. Hardy is often cited by papers focused on Multiple Sclerosis Research Studies (31 papers), Peripheral Neuropathies and Disorders (20 papers) and Retinal and Optic Conditions (9 papers). Todd A. Hardy collaborates with scholars based in Australia, United States and United Kingdom. Todd A. Hardy's co-authors include Peter J. Roach, David H. Miller, Wallace Brownlee, Franz Fazekas, Stephen Reddel, Michael Barnett, Illés J. Farkas, James A. Brock, Dongqing Huang and Claudia F. Lucchinetti and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and SHILAP Revista de lepidopterología.

In The Last Decade

Todd A. Hardy

66 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Diagnosis of multiple sclerosis: progress and challenges

2016 447 citations Todd A. Hardy et al. profile →

Peers

Countries citing papers authored by Todd A. Hardy

Since Specialization

Citations

This map shows the geographic impact of Todd A. Hardy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Todd A. Hardy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Todd A. Hardy more than expected).

Fields of papers citing papers by Todd A. Hardy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Todd A. Hardy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Todd A. Hardy. The network helps show where Todd A. Hardy may publish in the future.

Co-authorship network of co-authors of Todd A. Hardy

This figure shows the co-authorship network connecting the top 25 collaborators of Todd A. Hardy. A scholar is included among the top collaborators of Todd A. Hardy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Todd A. Hardy. Todd A. Hardy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Serum Lipid Profile of Relapsing Multiple Sclerosis Differs Reproducibly From Healthy Controls 2025 ·Journal of Neurochemistry ·(unknown), Laura Ghezzi, Georgia Watt, (unknown), Dana C. Perantie, Chiara Fenoglio, Collin Tran, (unknown), Freda Passam, Monokesh K. Sen, H.-Y. Chan, (unknown), Chenyu Wang, Michael J. Barnett, Todd A. Hardy, Laura Piccio, Anthony S. Don	0
2	Application of the ADEM definition to cerebral attacks of MOG antibody-associated disease 2025 ·Multiple Sclerosis Journal ·(unknown), (unknown), (unknown), John J. Chen, Vyanka Redenbaugh, Samantha A. Banks, Laura Cacciaguerra, Cristina Valencia-Sánchez, A. Sebastian López‐Chiriboga, Elia Sechi, Jan‐Mendelt Tillema, Deena Tajfirouz, Michael R. Basso, Todd A. Hardy, (unknown), Kai Guo, Sean J. Pittock, Eoin P. Flanagan	1
3	Cognitive behavioural therapy for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis 2024 ·Multiple Sclerosis and Related Disorders ·(unknown), (unknown), Todd A. Hardy	1
4	Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination 2024 ·Multiple Sclerosis and Related Disorders ·(unknown), Sudarshini Ramanathan, Cecilia Cappelen‐Smith, Steve Vucic, Stephen Reddel, Todd A. Hardy	3
5	Prime Editor Gene Therapy and TREX1 Mosaicism in Retinal Vasculopathy with Cerebral Leukoencephalopathy 2024 ·Journal of Clinical Immunology ·Samuel D. Chauvin, (unknown), Subhajit Poddar, Cathrine A. Miner, (unknown), (unknown), (unknown), Todd A. Hardy, Jonathan J. Miner	2
6	CSF sphingolipids are correlated with neuroinflammatory cytokines and differentiate neuromyelitis optica spectrum disorder from multiple sclerosis 2024 ·Journal of Neurology Neurosurgery & Psychiatry ·(unknown), Laura Ghezzi, Chiara Fenoglio, Anna M. Pietroboni, Daniela Galimberti, (unknown), Todd A. Hardy, Laura Piccio, Anthony S. Don	3
7	Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series 2024 ·Journal of Neuroimmunology ·(unknown), Todd A. Hardy	0
8	Induction cyclophosphamide with maintenance immunosuppression in high-risk myasthenia gravis: long-term follow-up and safety profile 2024 ·Journal of Neurology Neurosurgery & Psychiatry ·Fiona Chan, Todd A. Hardy, (unknown), Sudarshini Ramanathan, Sean Riminton, Stephen Reddel	1
9	The Impact of Relapses on Pain and Quality of Life in Patients with Multiple Sclerosis Treated with Corticosteroids 2023 ·Pharmaceuticals ·Martin Rakuša, Jeremy Chataway, Todd A. Hardy	1
10	Structural and functional markers of optic nerve damage in myelin oligodendrocyte glycoprotein antibody-associated optic neuritis 2021 ·Multiple Sclerosis Journal - Experimental Translational and Clinical ·Stephanie L. Barnes, Yuyi You, Ting Shen, Todd A. Hardy, Clare L. Fraser, Stephen Reddel, Fabienne Brilot, Sudarshini Ramanathan, Alexander Klistorner, Con Yiannikas	6
11	Investigation of tumefactive demyelination is associated with higher economic burden and more adverse events compared with conventional multiple sclerosis 2019 ·Multiple Sclerosis and Related Disorders ·Matthew Silsby, (unknown), Judith Spies, (unknown), Joshua Barton, Heidi Beadnall, Michael Barnett, Stephen Reddel, Todd A. Hardy	7
12	Immune-mediated conditions affecting the brain, eye and ear (BEE syndromes) 2019 ·Journal of Neurology Neurosurgery & Psychiatry ·James Triplett, Katherine Buzzard, Michal Lubomski, Sean Riminton, Michael Barnett, Miriam S. Welgampola, G. Michael Hálmagyi, (unknown), Klara Landau, Andrew G. Lee, Gordon T. Plant, Clare L. Fraser, Stephen Reddel, Todd A. Hardy	20
13	A systematic checklist approach to immunosuppression risk management: An audit of practice at two clinical neuroimmunology centers 2017 ·Journal of Neuroimmunology ·(unknown), Smriti Agarwal, (unknown), (unknown), Todd A. Hardy, Alasdair Coles, Stephen Reddel, Sean Riminton	2
14	Atypical inflammatory demyelinating syndromes of the CNS 2016 ·The Lancet Neurology ·Todd A. Hardy, Stephen Reddel, Michael Barnett, Jacqueline Palace, Claudia F. Lucchinetti, Brian G. Weinshenker	97
15	The corpus callosum in the diagnosis of multiple sclerosis and other CNS demyelinating and inflammatory diseases 2015 ·Journal of Neurology Neurosurgery & Psychiatry ·Nidhi Garg, Stephen Reddel, David Miller, Jeremy Chataway, Sean Riminton, Yael Barnett, Lynette Masters, Michael Barnett, Todd A. Hardy	51
16	Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder 2011 ·Diabetes Obesity and Metabolism ·Todd A. Hardy, Robert R. Henry, Tammy Forrester, (unknown), (unknown), David M. Marks, Sunder Mudaliar	14
17	A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes 2011 ·Diabetes Obesity and Metabolism ·Peggy L. Barrington, Jenny Y. Chien, H. D. Hollis Showalter, Karen Schneck, Shichao Cui, Fabián Tibaldi, Bernice Ellis, Todd A. Hardy	95
18	Guillain-Barré Syndrome: Modern Theories of Etiology 2011 ·Current Allergy and Asthma Reports ·Todd A. Hardy, Stefan Blum, Pamela McCombe, Stephen Reddel	47
19	Effects of a selective neuropeptide Y Y₂ receptor antagonist, BIIE0246, on Y₂ receptors at peripheral neuroeffector junctions 2001 ·British Journal of Pharmacology ·(unknown), Todd A. Hardy, James A. Brock, Erica K. Potter	56
20	Effects of modulating Ca 2+ entry and activating prejunctional receptors on facilitation of excitatory junction potentials in the guinea-pig vas deferens in vitro 2001 ·Naunyn-Schmiedeberg s Archives of Pharmacology ·Todd A. Hardy, James A. Brock	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact